uploads///headache _

Analyzing PTC Therapeutics’ Performance in September


Sep. 14 2018, Updated 12:30 p.m. ET

Stock performance

On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.

On September 13, PTC Therapeutics’ stock price closed at $47.33, which represents ~264% growth from its 52-week low of $14.56 on September 26, 2017.

Notably, PTC Therapeutics’ stock price hit its 52-week high of $52.95 on June 18. PTC Therapeutics’ stock price grew from $17.46 on January 2 to 47.33 on September 13, which represents ~203% year-to-date growth.

Article continues below advertisement

Recent developments

In August, PTC Therapeutics completed the acquisition of Agilis Biotherapeutics. The acquisition addeds Agilis Biotherapeutics’ important portfolio GT-AADC, an adeno-associated virus gene therapy that has the potential to treat Aromatic L-Amino Acid Decarboxylase deficiency, into PTC Therapeutics’ portfolio. PTC Therapeutics also added other gene therapy programs to its portfolio like GT-FA, GT-AS, and GT-RLN.

The GT-FA gene therapy program is associated with Friedreich Ataxia, while the GT-AS gene therapy program is associated with cognitive disorders related to Angelman syndrome. The GT-RLN gene therapy program is associated with various neurodegenerative disorders.

Product performance

In the second quarter, Translarna witnessed 4% growth year-over-year to $47.8 million from 45.8 million in the second quarter of 2017.

In the second quarter, Emflaza generated net revenues of $20.3 million—compared to $2.1 million in the second quarter of 2017.

Article continues below advertisement

Analysts’ recommendations

Of the eight analysts tracking PTC Therapeutics in September, two recommended a “strong buy,” while two recommended a “buy.” Three analysts recommended a “hold” and one recommended “sell” rating for PTC Therapeutics in September.

On September 13, PTC Therapeutics had a consensus 12-month target price of $42.17, which is an ~10.90% decline over the next 12 months.

Peers’ ratings

Of the 21 analysts tracking Sarepta Therapeutics (SRPT) in September, ~91% recommended a “buy.” Of the seven analysts tracking Amicus Therapeutics (FOLD), ~71% recommended a “buy.”

On September 13, Sarepta Therapeutics and Amicus Therapeutics had consensus 12-month target prices of $188.58 and $20.0, respectively, which is an ~25.54% and ~72.41% return on investment over the next 12 months.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.